This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (24)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Immunotherapy  • Alert me on articles by topic

A Topically Applied Link Between Innate and Acquired Immunity

Arch Dermatol. 2003;139:1347-1350.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IMIQUIMOD IS a topically applied imidazoquinoline immunomodulator that has been shown to have efficacy in a wide range of infectious and neoplastic dermatologic conditions. This has generated some skepticism about how any single drug can work for so many indications. In 1997, it was approved for treating external perianal and genital warts.¹ In addition, there are open-label trials and case reports showing success in treating of other virus-related conditions including flat warts² and molluscum contagiosum.³ There are similar reports demonstrating successful treatment of intraepithelial neoplasms including Bowen disease,⁴ lentigo maligna,⁵ and extramammary Paget disease.⁶ A recent case report showed efficacy in treating cutaneous T-cell lymphoma.⁷ Imiquimod has also been used to effectively treat other neoplastic conditions such as actinic keratosis⁸ and superficial basal cell carcinoma.⁹

In this issue of the ARCHIVES, Urosevic et al¹⁰ make a significant contribution to elucidating the time course of imiquimod action in superficial basal cell . . . [Full Text of this Article]

PLEIOTROPIC EFFECTS OF IMIQUIMOD


TOLL RECEPTORS

IMIQUIMOD FUNCTIONS VIA TLR7
Daniel J. Hurwitz, MD; Laura Pincus, AB; Thomas S. Kupper, MD
Harvard Skin Disease Research Center
Department of Dermatology
Brigham and Women's Hospital
Boston, MA 02115
(e-mail: tskupper@rics.bwh.harvard.edu

RELATED ARTICLE

Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo
Mirjana Urosevic, Tanja Maier, Bernd Benninghoff, Herbert Slade, Guenter Burg, and Reinhard Dummer
Arch Dermatol. 2003;139(10):1325-1332.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells
Clark et al.
JEM 2008;205:2221-2234.
ABSTRACT | FULL TEXT  

Treatment of Atypical Nevi With Imiquimod 5% Cream
Somani et al.
Arch Dermatol 2007;143:379-385.
ABSTRACT | FULL TEXT  

Hemangiomas of Infancy: Clinical and Biological Characteristics
Smolinski and Yan
CLIN PEDIATR 2005;44:747-766.
ABSTRACT  

Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod
Wolf et al.
Arch Dermatol 2005;141:510-514.
ABSTRACT | FULL TEXT  

The Pyrin Family of Fever Genes: Unmasking Genetic Determinants of Autoinflammatory Disease
Shinkai et al.
Arch Dermatol 2005;141:242-247.
FULL TEXT